The expanding spectrum of biological actions of vitamin D

Jorge Rojas-Rivera1,2, C. De La Piedra3, Ana Ramos1, Alberto Ortiz1,4 and Jesús Egido1,4

1IIS-Fundación Jimenez Diaz, Division of Nephrology and Hypertension, Laboratory of Experimental Nephrology and Vascular Pathology, Madrid, Spain, 2International Fellowship Program of International Society of Nephrology (ISN), Global Operations Center, Rue du Luxembourg 22-24, B-1000, Brussels, Belgium, 3Biochemistry Laboratory, Fundación Jimenez Diaz, Madrid, Spain and 4Universidad Autonoma de Madrid, Madrid, Spain

Correspondence and offprint requests to: Jorge Rojas-Rivera; E-mail: jerori2003@yahoo.com

Research support: International Society of Nephrology (ISN)—International Fellowship Program to Jorge Rojas-Rivera. ISCII grants RETIC/REDINREN 06/0016 and PS09/00447 to Alberto Ortiz.

Keywords: cardiovascular outcomes; nephroprotection; non-calcitropic actions; renal outcomes; vitamin D deficiency

Introduction

The vitamin D hormonal system was classically implicated in the regulation of calcium homeostasis and bone metabolism. However, it also has extra-mineral metabolism functions through activation of non-renal vitamin D receptor (VDR) [1]. Vitamin D deficiency is an increasingly recognized public health problem in the general population and in chronic inflammatory disorders such as chronic kidney disease (CKD) [2,3]. Newly uncovered actions of the vitamin D hormone system could underlie the impact of vitamin D deficiency and supplementation on prognosis in CKD and non-CKD patients.

We review emerging extra-mineral metabolism functions of vitamin D from a translational perspective, highlighting recent information on vitamin D deficiency, replacement therapy, pathogenesis, and outcomes in cardiovascular, inflammatory and renal disease.

Vitamin D

Vitamin D3 (ergocalciferol) is obtained from certain food and, principally, from vitamin supplements. Vitamin D3 (VD3, cholecalciferol) is present in food and vitamin supplements, but is mainly generated by skin exposed to ultraviolet B radiation: 7- and 8-dehydrocholesterol are converted by photolysis to pre-VD3 and then by thermal isomerization, to VD3. This pro-hormone is converted to 25-hydroxycholecalciferol [25(OH)D] in the liver by 1-α-hydroxylase and stimulation of 24-hydroxylase), potentiates the effects of PTH on calcium reabsorption, and induces transepithelial calcium transport by TRPV5, cytosolic calcium-binding protein (CaBP or calbindin), ATPase, Ca2+-ATPase pump, and Na+/Ca2+ exchanger [1]. In the renal tubule, calcitriol controls its own homeostasis (suppression of 1-α-hydroxylation and stimulation of 24-hydroxylase), potentiates the effects of PTH on calcium reabsorption, and induces transepithelial calcium transport by TRPV5, calbindin, and Ca2+-ATPase pump [1,5]. Additionally, calcitriol increases bone osteoclastic activity and suppresses PTH release [1-4] (Figure 1).

There is no definite consensus about which serum 25(OH)D level better defines vitamin D deficiency. Applying the criteria of 25(OH)D levels required to suppress PTH, deficiency is defined as 25(OH)D <20 ng/mL (50 nmol/L) and relative insufficiency 21–29 ng/mL [6-8]. A target ≥30 ng/mL (75 nmol/L) has been suggested to be desirable for optimal health and for cancer prevention [6,9–11]. Less than 9% of older US whites and a smaller fraction of Mexican American and African American adults had serum 25(OH)D ≥36 ng/mL [12]. More than a billion people in the world have 25(OH)D levels <30 ng/mL [2]. This situation affects 40–50% of all age groups and both sexes [2,13]. In the National Health and Nutrition Examination Survey (NHANES), prevalence of 25(OH)D <10 ng/mL increased from 2% to 6%, and prevalence of >30 ng/mL levels decreased from 45% to 23% in the past decade [14]. One-third of black pregnant women and 5% of white pregnant women have 25(OH)D levels <10 ng/mL.
women in the USA had 25(OH)D levels <15 ng/mL [15]. In Spain, 49% of 2230 ambulatory patients had 25(OH)D <30 ng/mL, 25% <20 ng/mL and 6.2% <10 ng/mL [16]. Vitamin D is required for bone and muscle health, and severe 25(OH)D deficiency causes rickets in children, and osteomalacia and myopathy in adults [17–19].

**Vitamin D deficiency in CKD**

In CKD, there is a widespread calcitriol deficiency and a high prevalence of 25(OH)D deficiency. The latter is due to poor sunlight exposure in chronically ill patients, decreased skin synthesis of cholecalciferol in response to sunlight, dietary restriction of vitamin D-rich food, and urine loss of 25(OH)D and DBP in proteinuric nephropathies [20–22]. In addition, renal maligean decreases with CKD progression, thus reducing 25(OH)D tubular reabsorption [23]. Even in dialysis patients, 25(OH)D supplementation can normalize serum calcitriol. This was attributed to an impaired availability of 25(OH)D, and suggests that the reduction of 1α-hydroxylase activity is not the only problem [24]. Recent CKD guidelines recommend monitoring and correcting 25(OH)D levels [8,25]. Calcitriol levels decline from the early stages of CKD, before any changes in serum calcium, phosphorus or PTH levels. This facilitates secondary hyperparathyroidism and metabolic bone disease, and is associated with higher rates of cardiovascular events [26–29].

25(OH)D deficiency is common in patients with nephrotic syndrome and normal renal function [30,31]. In nephrotic syndrome and sub-nephrotic range proteinuria, there was an inverse relationship between serum 25(OH)D and DBP [32–34]. In NHANES III, low serum 25(OH)D levels were associated with an increased prevalence of albuminuria. This association was independent of age, sex, ethnicity, smoking status, body mass index and kidney function, and persisted for serum 25(OH)D <24.1 ng/mL in the presence of hypertension and diabetes [35].

In CKD, fibroblast growth factor-23 (FGF-23) could contribute to further reduce 25(OH)D and 1,25(OH)D levels [36–38]. Even in early stages of CKD, renal retention of phosphorus may contribute the impaired production of 1,25(OH)D directly, and by increasing FGF-23 levels. FGF-23 from osteocytes activates the FGFR1 receptor in the presence of Klotho co-receptor to induce phosphaturia, suppress renal 1α-hydroxylase activity, suppress PTH production and increase 1,25(OH)D or 25(OH)D catabolism by activating 24-hydroxylase [1,39]. Thus, FGF-23 could contribute to both 25(OH)D and 1,25(OH)D deficiency in CKD. In advanced CKD, the phosphaturic effect of FGF-23 is limited by the low glomerular filtration rate (GFR). However, 1α-hydroxylase activity is still suppressed, and serum phosphorus remains high despite high FGF-23 levels [40]. Calcium deprivation promotes 25(OH)D D depletion [41]. This is thought to result from increased PTH, which promotes the conversion of 25(OH)D to 1,25(OH)D. 1,25(OH)D itself stimulates hepatic inactivation of 25(OH)D [41] by an enzyme later identified as 24-hydroxylase, leading to 24,25(OH)D synthesis [22]. Current knowledge of basic physiology of vitamin D (Figure 1) and of its deficiency in CKD has improved the management of mineral metabolism by dietary phosphorus restriction, use of phosphorus binders, vitamin D analogues and calcimimetics [42,43]. However, further studies are needed to improve our understanding of the PTH/FGF-23–Klotho/vitamin D axis.

Vitamin D has actions beyond calcium–phosphorus–PTH axis regulation. These actions depend on renal and extra-renal 1α-hydroxylase activity, and are mediated by VDR in immune system cells, breast, colon, prostate, kidney, intestine, pancreas and other tissues [44].

Peripheral 1α-hydroxylation of 25(OH)D to 1,25(OH)D depends on substrate [25(OH)D] availability and the activity of local 1α-hydroxylase and 24-hydroxylase. Extra-renal 1α-hydroxylase is not regulated by PTH or FGF-23, but it is activated by inflammatory mediators. Local 1,25(OH)D activates the VDR in an autocrine or paracrine manner [45,46]. These features may better explain the impact of 25(OH)D deficiency on renal and cardiovascular outcomes, diabetes, glucose intolerance, metabolic syndrome, obesity, pre-eclampsia, and hypertension [47–53].

**Clinical studies on vitamin D deficiency**

*Vitamin D status and cardiovascular outcomes in non-CKD patients*

Observational studies have demonstrated the relationship between 25(OH)D deficiency and cardiovascular outcomes in patients without CKD, including all-cause mortality, hypertension, cardiovascular disease, myocardial infarction, stroke, prevalence of peripheral arterial disease, and cancer mortality. This association was also shown in older population (Table 1) [28,47–58]. After confounder adjustment, a serum 25(OH)D level <20 ng/mL doubled the risk of pre-eclampsia, a predictor of chronic hypertension and CKD [53–56]. In critically ill patients, the prevalence of low 25(OH)D was high, and low 25(OH)D values were associated with adverse outcome [59]. However, additional research is needed on the potential contribution of confounding factor such as a sedentary lifestyle, special dietary needs, or co-
existence of non-renal chronic inflammatory disorders to both the lower 25(OH)D values and worse outcomes.

Vitamin D replacement and cardiovascular outcomes in non-CKD patients

There are a few clinical trials supporting the cardiovascular benefit of treating vitamin D deficiency in the non-uraemic population (Table 1). A small placebo-controlled trial observed that cholecalciferol 50 μg/day (1 μg=40 IU) decreased PTH and tumour necrosis factor-α, and increased anti-inflammatory cytokine interleukin-10 [60]. A mean daily cholecalciferol intake of 528 IU (300–2000) lowered mortality despite a relatively short follow-up [61]. In a recent meta-analysis of 57 311 patients from 18 randomized clinical trials, the relative risk for all-cause mortality was 0.93 (95% CI 0.87–0.99) in vitamin D-supplemented patients [62]. However, the primary end points in most studies were conditions associated with higher mortality such as clinical fractures, falls or bone mineral density. A randomized, multicentre study in post-menopausal women failed to show a benefit of 1000 mg/day calcium carbonate plus 400 IU/day VD3 on the secondary outcome risk of heart disease or cerebrovascular events [52]. A possible explanation for the lack of impact on cardiovascular outcomes is the lower than expected prevalence of serum 25(OH)D <30 ng/mL. Serum 25(OH)D was not analysed as an interaction factor to the major outcomes. As the impact of therapy on 25(OH)D levels was not assessed, it is unclear whether the relatively low dose of VD3 improved serum 25(OH)D.

Vitamin D deficiency: therapy and cardio-renal outcomes in CKD and dialysis patients

Observational studies. Vitamin D deficiency is prevalent in CKD and, especially, in chronic haemodialysis patients. Our group found 25(OH)D <20 ng/mL in 83% and <10 ng/mL in 25% of haemodialysis patients. No patient had levels >40 ng/mL [63]. The levels of 25(OH)D were lower in patients evaluated in February than in patients evaluated in December (13.4±5.2 vs 17.4±6.1 ng/mL, P<0.002), highlighting the progressive decrease of 25(OH)D stores during winter. Serum 1,25(OH)D was low in all patients.

Vitamin D replacement and outcomes

Table 1. Principal studies on vitamin D status and replacement and major clinical outcomes in non-CKD patients

<table>
<thead>
<tr>
<th>Study</th>
<th>Population</th>
<th>n</th>
<th>Age (years)</th>
<th>Follow-up (years)</th>
<th>Serum 25(OH)D (ng/mL)</th>
<th>Outcome</th>
<th>RR/OR (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dobnig [28]</td>
<td>Elders</td>
<td>3258</td>
<td>62</td>
<td>7.7</td>
<td>&lt;13.3</td>
<td>All-cause mortality</td>
<td>1.5 (1.2–2.0)</td>
</tr>
<tr>
<td></td>
<td>CV symptoms</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>CV mortality</td>
<td>1.8 (1.3–2.6)</td>
</tr>
<tr>
<td>Wang [47]</td>
<td>Healthy volunteers</td>
<td>1739</td>
<td>59</td>
<td>5.4</td>
<td>&lt;15</td>
<td>CV disease</td>
<td>1.6 (1.1–2.4)</td>
</tr>
<tr>
<td>Giovannucci [48]</td>
<td>Healthy volunteers</td>
<td>18 225</td>
<td>40–75</td>
<td>10</td>
<td>&lt;15</td>
<td>AMI</td>
<td>2.1 (1.2–3.5)</td>
</tr>
<tr>
<td>Pilz [49]</td>
<td>CV symptoms</td>
<td>3316</td>
<td>54.8–76.0</td>
<td>7.8</td>
<td>0.19–0.5g6</td>
<td>Fatal stroke</td>
<td>0.7 (0.5–0.9)</td>
</tr>
<tr>
<td>Melamed [50]</td>
<td>NHANES</td>
<td>4839</td>
<td>56.2</td>
<td>No follow-up</td>
<td>&lt;17.8</td>
<td>PAD</td>
<td>1.8 (1.2–2.7)</td>
</tr>
<tr>
<td>Bodnar [51]</td>
<td>Pregnant women</td>
<td>274</td>
<td>14–44</td>
<td>Pregnancy</td>
<td>&lt;20</td>
<td>Pre-eclampsia</td>
<td>2.4 (1.1–5.4)</td>
</tr>
<tr>
<td>Forman [53]</td>
<td>Healthy volunteers</td>
<td>1811</td>
<td>40–75</td>
<td>4–8</td>
<td>&lt;15</td>
<td>Hypertension</td>
<td>3.2 (1.4–7.3)</td>
</tr>
<tr>
<td>Melamed [57]</td>
<td>NHANES</td>
<td>13 331</td>
<td>41–47</td>
<td>6–12</td>
<td>&lt;17.8</td>
<td>All-cause mortality</td>
<td>1.26 (1.08–1.46)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>CV mortality</td>
<td>1.20 (0.87–1.64)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Cancer mortality</td>
<td>0.91 (0.63–1.31)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>All-cause mortality</td>
<td>2.1 (1.22–3.64)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>CV mortality</td>
<td>2.64 (1.14–4.79)</td>
</tr>
</tbody>
</table>

Vitamin D status and outcomes

<table>
<thead>
<tr>
<th>Study</th>
<th>Population</th>
<th>n</th>
<th>Age (years)</th>
<th>Follow-up (years)</th>
<th>Serum 25(OH)D (ng/mL)</th>
<th>Outcome</th>
<th>RR/OR (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hsia [52]</td>
<td>Post-menopausal women</td>
<td>36 282</td>
<td>50–79</td>
<td>7 years</td>
<td>Ca 0.5 g/day+VD3 400 IU vs Ca 0.5 g/day+placebo 6.5 years VD3 50 μg/d+Ca 0.5 g/day vs Placebo+Ca 0.5 g/day</td>
<td>Heart disease</td>
<td>1.0 (0.9–1.2)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Stroke</td>
<td>0.95 (0.8–1.1)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Patient survival</td>
<td>85.7% vs 88.2%</td>
</tr>
<tr>
<td>Schleithoff [60]</td>
<td>German CHF patients</td>
<td>123</td>
<td>50–63</td>
<td>15 months</td>
<td>Ca 0.5 g/day+Ca 0.5 g/day+placebo 6.5 years VD3 50 μg/d+Ca 0.5 g/day vs Placebo+Ca 0.5 g/day</td>
<td>TNF-α</td>
<td>2 vs +2.7 pg/mL</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>ProANP/ProBNP</td>
<td>ND</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>All-cause mortality</td>
<td>0.93 (0.87–0.99)</td>
</tr>
<tr>
<td>Autier [62][b]</td>
<td>Cardiac, older</td>
<td>57 311</td>
<td>47–92</td>
<td>5.7 years (0.5–7)</td>
<td>Ca 0.5 g/day+Ca 0.5 g/day+placebo 6.5 years VD3 50 μg/d+Ca 0.5 g/day vs Placebo+Ca 0.5 g/day</td>
<td>Heart disease</td>
<td>1.0 (0.9–1.2)</td>
</tr>
<tr>
<td></td>
<td>and high-risk fracture</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Stroke</td>
<td>0.95 (0.8–1.1)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Patient survival</td>
<td>85.7% vs 88.2%</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>TNF-α</td>
<td>2 vs +2.7 pg/mL</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>ProANP/ProBNP</td>
<td>ND</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>All-cause mortality</td>
<td>0.93 (0.87–0.99)</td>
</tr>
</tbody>
</table>

AMI, acute myocardial infarction; CI, confidence interval; CHF, congestive heart failure; CKD, chronic kidney disease; CV, cardiovascular; ND, no difference; NHANES, National Health and Nutrition Examination Survey; OR, odds ratio; PAD, peripheral arterial disease; ProANP and ProBNP, propeptide atrial and brain natriuretic peptide; RCT, randomized clinical trials; RR, relative risk; TNF-α, tumour necrosis factor-alpha; VD2, ergocalciferol; VD3, cholecalciferol.

[b]Corresponded to Z-standardized values.
[c]Corresponded to a meta-analysis.
[d]Lowest vs highest quartile.
[e]To convert to nmol/L multiply 2.496.
### Table 2. Principal studies on vitamin D status and replacement and major clinical outcomes in CKD patients

#### Vitamin D status and outcomes

| Study          | Population       | n   | Age (years) | Follow-up (years) | Serum 25(OH)D (ng/mL)
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Wang [69]</td>
<td>PD, Asian</td>
<td>230</td>
<td>55 ± 12</td>
<td>3</td>
<td>&gt;18.3</td>
</tr>
<tr>
<td>Melamed [70]</td>
<td>NHANES III</td>
<td>13 328</td>
<td>44.3 ± 0.5</td>
<td>9.1</td>
<td>&lt;15</td>
</tr>
<tr>
<td>Ravani [72]</td>
<td>CKD 2–5</td>
<td>168</td>
<td>70.1 ± 11.9</td>
<td>4</td>
<td>215</td>
</tr>
<tr>
<td>Mehrotra [74]</td>
<td>CKD, NHANES III</td>
<td>3011</td>
<td>55.4 ± 0.9</td>
<td>9</td>
<td>&lt;15</td>
</tr>
</tbody>
</table>

#### Vitamin D replacement and outcomes

<table>
<thead>
<tr>
<th>Study</th>
<th>Population</th>
<th>n</th>
<th>Age (years)</th>
<th>Follow-up</th>
<th>Comparison</th>
<th>Outcome</th>
<th>RR/OR (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tentori [65]</td>
<td>Incident HD</td>
<td>7731</td>
<td>48.5</td>
<td>5.75 years</td>
<td>Paricalcitol vs calcitriol</td>
<td>All-cause mortality</td>
<td>0.95 (0.79–1.13)</td>
</tr>
<tr>
<td>Teng [66]</td>
<td>Prevalent HD</td>
<td>67 399</td>
<td>61.0</td>
<td>3 years</td>
<td>Paricalcitol vs calcitriol</td>
<td>All-cause mortality</td>
<td>0.95 (0.77–1.18)</td>
</tr>
<tr>
<td>Teng [67]</td>
<td>Incident HD</td>
<td>51 037</td>
<td>61.5</td>
<td>2 years</td>
<td>Injectable calcitriol agonists</td>
<td>All-cause mortality</td>
<td>1.0 (0.82–1.121)</td>
</tr>
<tr>
<td>Naves-Diaz [68]</td>
<td>Incident and prevalent HD</td>
<td>16 094</td>
<td>58.4</td>
<td>16 months</td>
<td>Calcitriol or alfacalcitrol vs non-users</td>
<td>Patient survival</td>
<td>0.55 (0.49–0.63)</td>
</tr>
<tr>
<td>Shoben [71]</td>
<td>CKD 3–4</td>
<td>1418</td>
<td>69 ± 10.3</td>
<td>1.9 years</td>
<td>Users vs non-users calcitriol</td>
<td>Mortality</td>
<td>0.76 (0.58–0.99)</td>
</tr>
<tr>
<td>Clinical trials</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Mortality+diabetes</td>
<td>0.80 (0.64–1.01)</td>
</tr>
<tr>
<td>Agarwal [77]</td>
<td>CKD 3–4</td>
<td>220</td>
<td>62.2</td>
<td>6 months</td>
<td>Paricalcitol (9.5 ug/week) vs placebo</td>
<td>Proteinuria reduction</td>
<td>3.2 (1.5–6.9)</td>
</tr>
<tr>
<td>Szeto [78]</td>
<td>IgA nephropathy</td>
<td>30</td>
<td>43.1 ± 9.9</td>
<td>3 months</td>
<td>Oral calcitriol (1.0 ug/week)</td>
<td>Proteinuria</td>
<td>1.9–3.5 g/g</td>
</tr>
<tr>
<td>Fishbane [79]</td>
<td>Proteinuric</td>
<td>61</td>
<td>57.8</td>
<td>6 months</td>
<td>Paricalcitol (1 ug/day) or placebo</td>
<td>Proteinuria reduction</td>
<td>57.1% vs 25.9%</td>
</tr>
<tr>
<td>Alborzi [80]</td>
<td>CKD 2–4</td>
<td>24</td>
<td>56–82</td>
<td>1 month</td>
<td>Paricalcitol (0, 1 and 2 ug/day)</td>
<td>24-h albuminuria</td>
<td>[35%, 44%]</td>
</tr>
<tr>
<td>VITAL [82]</td>
<td>Diabetic</td>
<td>281</td>
<td>64.9 ± 10.4</td>
<td>6 months</td>
<td>Paricalcitol (0, 1 and 2 ug/day)</td>
<td>Albuminuria</td>
<td>P=0.015*</td>
</tr>
</tbody>
</table>

CI, confidence interval; CKD, chronic kidney disease; CRP, C-reactive protein; CV, cardiovascular; ESRD, end-stage renal disease; HD, haemodialysis; NHANES, National Health and Nutrition Examination Survey; OR, odds ratio; PD, peritoneal dialysis; PTH, parathyroid hormone; RR, relative risk; VDRa, VDR activators.

*aFor decrease of 10% in proteinuria.

*bFor decrease of 24-h albuminuria evaluated as % geometric mean change.

For decrease of urinary albumin–creatinine ratio evaluated as % geometric mean change.

*dTo convert to nmol/L multiply by 2.496.
oral paricalcitol (mean dose 9.5 μg/day) was associated with reduced all-cause, cardiovascular, infectious diseases and cancer mortality [68]. In a prospective cohort study of peritoneal dialysis patients followed up for 3 years, the lowest 25(OH)D levels were associated with increased risk of cardiovascular events, although this effect was influenced by the degree of left ventricular hypertrophy and diastolic dysfunction [69]. Studies in patients with more preserved renal function (not on dialysis) are scarce. The impact of low 25(OH)D levels on CKD progression should be studied. In NHANES III, serum 25(OH)D <15 ng/mL was associated with the development of end-stage renal disease (ESRD) even after adjustment for several risk factors [70]. Non-dialysis CKD patients could benefit from calcitriol or paricalcitol therapy. In 1418 patients with CKD stages 3–4 and hyperparathyroidism followed up for 1.9 years, the use of oral calcitriol was associated with a 26% lower risk of death or admission to dialysis, but it was also associated with an increased risk of hypercalcaemia [71]. In 168 incident patients with CKD stages 2–4 followed up for a mean of 4 years, the basal 25(OH)D level was an independent predictor of progression to ESRD and death when adjusted for relevant variables [72]. In 140 CKD patients, including 10 in dialysis, 25(OH)D <16.7 ng/mL influenced the risk of death after adjustment for several cardiovascular risk factors [73]. Serum albumin was the only variable significantly correlated with serum 25(OH)D, but unfortunately, proteinuria was not evaluated by multivariable regression. In the largest study of the relationship between serum 25(OH)D and death in CKD, levels <15 ng/mL versus >30 ng/mL were associated with ∼50% higher cardiovascular and all-cause mortality [74]. In these studies, the high mortality in CKD patients with 25(OH)D deficiency cannot be exclusively attributed to cardiovascular events. Similar to the general population, serious infections or cancer is a condition associated with 25(OH)D deficiency [60,75]. In summary, 25(OH)D deficiency is associated with undesirable clinical outcomes in CKD patients. However, due to the observational design of most studies, randomized clinical trials are necessary to improve the quality of evidence on the survival advantage offered by vitamin D therapy in patients with advanced CKD [76].

Clinical trials. Clinical trials evaluated the impact of VDR activators on proteinuric CKD [77–80] (Table 2). In a double-blind, randomized, placebo-controlled trial of oral paricalcitol (mean dose 9.5 μg/week) in 220 patients with CKD stages 3–4 with secondary hyperparathyroidism, paricalcitol reduced dipstick proteinuria (51% vs 25% for placebo). However, proteinuria was not a primary outcome and was measured semi-quantitatively, and the follow-up was too short (24 weeks) [77]. In a small open-label prospective uncontrolled trial, 10 patients with IgA nephropathy and persistent proteinuria despite renin–angiotensin–aldosterone system (RAAS) blockade received calcitriol 0.5 μg, twice weekly for 12 weeks [78]. There was a modest antiproteinuric effect (urine protein–creatinine ratio decreased from 1.98±0.7 to 1.48±0.8 g/g in 6 weeks), without significant changes in blood pressure or renal function. A double-blind randomized study comparing paricalcitol 1 μg/day or placebo for 6 months in 61 patients with proteinuric kidney disease showed a significant reduction in proteinuria (+3% for controls and −18% for paricalcitol) [79]. In a randomized double-blind trial, oral paricalcitol (1 or 2 μg/day for 1 month) reduced inflammation [high-sensitivity C-reactive protein (hs-CRP)] and albuminuria without changes in endothelial function (flow-mediated dilatation and vascular smooth muscle function), blood pressure, GFR, or PTH levels in 24 patients with CKD stages 2–3 and RAAS blockers [80].

The VITAL double-blind, randomized, placebo-controlled study evaluated the anti-albuminuric effect of paricalcitol 1 or 2 μg/day versus placebo in 281 patients with CKD stages 2–4, diabetic nephropathy, and standard therapy to control blood pressure and proteinuria [81]. There was only a trend towards reduced albuminuria in the primary outcome measure (albumin/creatinine ratio), but in additional outcome measures, 2 μg/day paricalcitol significantly but reversibly reduced 24-h albuminuria at 24 weeks [82]. Paricalcitol 2 μg/day reversibly reduced blood pressure (0 to −10 mmHg), a beneficial effect beyond action on proteinuria, but it also reduced the estimated GFR (0 to −6 mL/min/1.73 m²). This change could be real or related to potential actions of paricalcitol on tubular creatinine secretion. In this regard, oral calcitriol for 6 months decreased creatinine clearance by 22% but did not change inulin or para-aminohippurate clearance, suggesting changes in creatinine secretion [83]. The incidence of hypercalcaemia was not increased. In all trials involving paricalcitol for proteinuria, serum 25(OH)D levels were <30 ng/mL in most patients.

We still need formal large randomized clinical trials supporting the benefits of treating 25(OH)D and calcitriol deficiency on relevant clinical outcomes (cardiovascular events, admission to dialysis and mortality), and comparing the different pharmacological agents available.

A systematic review of 16 randomized clinical trials (894 patients with CKD without dialysis) concluded that several vitamin D compounds (calcitriol, alfalcacidol, doxercalciferol, paricalcitol and maxacalcitol) did not alter mortality or need for dialysis, but decreased serum PTH and increased serum phosphorus and calcium [84]. This review did not evaluate the changes in proteinuria or serum 25(OH)D with therapy and considered active and non-active compounds, and some trials were too short or did not evaluate cardiovascular outcomes.

1,25-Dihydroxyvitamin D and VDR: biology, extra-bone functions and therapeutic modulation

Basic molecular biology and genomic actions of VDR
The biological actions of calcitriol and its active synthetic analogues are mediated by the VDR which is an ubiqui-
tous, ligand-activated transcription factor belonging to the superfamily of steroid/thyroid hormone receptors [85]. There are four steps for VDR control of gene transcription: (i) ligand binding in the C-terminal portion of VDR (ligand-binding domain, LBD), (ii) heterodimerization with retinoid X receptor (RXR) at the LBD and nuclear translocation, (iii) binding of VDR–RXR by the DNA-binding domain of VDR to specific DNA sequences in the promoter region of target genes (VD response elements, VDREs), and (iv) recruitment of VDR-interacting nuclear proteins or DRIPs (co-regulators or co-factors) which determine gene transactivation or transrepression [1,86,87] (Figure 2). The main co-activators are the steroid receptor co-activator family (SRC-1, SRC-2 and SRC-3) and CREB-binding protein (CBP/p300) [1]. Co-activators modify chromatin via histone acetylation, recruit transcription mediator complexes, regulate ligand-dependent posttranslational modification, and provide DNA helicase and protein kinase activity. The main co-repressors are NcoR-1, NcoR-2 and Hairless which de-acetylate histone lysine residues, compact chromatin, and silence genes (chromatin remodelling) [86,88]. The VDR co-modulator NCoA62/Skip may have a bifunctional role, promoting activation or repression, depending on the relative levels of NcoR and CBP/300 [89]. Calcitriol itself could modulate the transcriptional activity through selective induction of TIF2 (a p160 co-activator) and/or SMRT (co-repressor) [90]. The final balance between co-activators and co-repressors determines the control of gene transcription in the presence of physiological and pathological stimuli.

25(OH)D binds nearly 100 times less avidly to VDR than calcitriol [1,91]. Since 25(OH)D levels are 1000 times higher than 1,25(OH)D concentration, VDR activation by 25(OH)D is likely. In addition, even in CKD patients with very low renal 1-α-hydroxylase, 25(OH)D supplementations increases serum 1,25(OH)D probably through non-renal 1-α-hydroxylases [92] (Figure 3).

**Non-genomic actions of VDR**

Calcitriol has rapid, non-genomic actions, such as activation of kinases, phosphatases, phosphoinositide metabolism, cytosolic calcium levels and cyclic GMP signalling pathways. The contribution of non-genomic actions to the pathophysiology of the vitamin D endocrine system remains controversial. One potential role is modulation of VDR genomic actions by phosphorylation of VDR co-regulators that influence VDR transcriptional activity. Uraemic conditions may also interfere with interactions between 1,25(OH)D–VDR–RXR, co-regulators and signalling pathways [93,94].

**Experimental studies in renal and vascular pathology: potential therapeutic modulation of VDR activation**

The main endocrine effect of 1,25(OH)D in the kidney is a tight control of its own homeostasis, by suppressing 1-α-hydroxylase, stimulating 24-hydroxylase and inducing megalin expression in proximal tubular cells [86,95]. Increased megalin expression could favour megalin-mediated protein uptake in renal tubules and thus, reduce proteinuria [81,86]. In addition, VDR activation has anti-proliferative, pro-differentiation and immunomodulator actions [1], which may modulate the development of osteoporosis, autoimmune, inflammatory and infectious diseases. The VDR axis also contributes to blood pressure and plasma volume homeostasis, cardiac function, and integrity of renal cells. A critical non-classical renal action is induction of type A natriuretic peptide receptor (NPR-A), a key regulator of urinary sodium [96]. VDR immunoregulatory and anti-inflammatory effects may regulate atherogenesis and kidney injury [97,98]. In cardiomyocytes, calcitriol inhibited cell proliferation and apoptosis, and enhanced cardiomyocyte formation [99]. In mesenchymal multi-potent cells, calcitriol activated the VDR and increased anti-fibrotic factors, such as bone morphogenic protein (BMP) 2, 7 and matrix metalloproteinase 8, and decreased expression of TGF-β1, plasminogen activator inhibitor-1, and collagens I and III [100]. In this regard, calcitriol led to regression of left ventricular hypertrophy and improved survival [101]. Clinical studies have demonstrated that RAAS inhibition slows the progression to ESRD in proteinuric CKD [102–105]. In hypertensive patients, renin activity is inversely related with plasma calcitriol levels [106]. VDR knockout mice or mice with deficient calcitriol synthesis developed hypertension and increased renin and angiotensin II expression and left ventricular hypertrophy, while the VDR activation decreased renin expression and left ventricular hypertrophy [107–110]. In Dahl salt-sensitive rats, paricalcitol decreased left ventricular mass, increased fractional ejection shortening, and lowered myocardium brain and atrial natriuretic peptides, and renin expression [111]. In uraemic rats, paricalcitol decreased renin, renin receptor, angiotensin II, angiotensin AT1 receptor, blood pressure, proteinuria, glomerular sclerosis, tubulointerstitial injury, vascular endothelial growth factor (VEGF) and TGF-ß [112]. VDR activation decreases inflammation and nuclear factor kappa B (NF-κB) activation in vivo and in cultured renal cells [113]. VDR activation is also nephroprotective in experimental diabetic nephropathy [114]. In patients with acute renal inflammation, decreased serum 1,25(OH)D and 25(OH)D were associated with increased renal inflammation (increased urinary macrophage chemoattractant protein-1) [115]. Yet, many aspects of the VDR–RAAS relationship remain poorly characterized, including the interaction between VDR and angiotensin AT2 receptor, a receptor mediating vasodilatation and inhibition of cell growth; the generation of angiotensin 1–7 (Mas receptor activator) from angiotensin II; or the interaction with angiotensin-converting enzyme 2, a cardio-renal protective enzyme [107,116].

The potential mechanisms involved in cardiovascular protection by calcitriol include anti-inflammation, antioxidants, inhibition of cardiac hypertrophy and proliferation of myocytes, and regulation of RAAS with preservation of renal function [117]. VDR activation by paricalcitol decreased the expression of genes involved in vascular cell growth, thrombogenicity, fibrinolysis and endothelial regeneration in human coronary artery vascular cells [118]. In humans, VDR activation reduced left ventricular hypertrophy in haemodialysis patients [119,120].
These findings provide a biological basis for the benefit afforded by VDR agonists in epidemiological studies. However, VDR activation may carry a risk of vascular calcification. Thus, while VD deficiency is associated with increased inflammation, reduced endothelial protecting factors and a pro-atherogenic status; VD overdose leads to hypercalcemia, and increases metalloproteinases, vascular calcification, arterial stiffness and left ventricular hypertrophy [121]. Vascular calcification may be a consequence of excessive suppression of PTH by VDR activators leading to a dynamic bone disease [122]. In a cross-sectional study of dialysis children treated with daily oral alfacalcidol, there was a U-shaped distribution for vascular disease [123]. Patients with high and low 1,25(OH)D levels had greater carotid intima-media thickness and calcification scores than patients with normal levels. Furthermore, 1,25 (OH)D levels showed a linear correlation with serum calcium–PO₄ product. Inflammation, assessed as hs-CRP, was higher in patients with vascular calcification and inversely correlated with 1,25(OH) D levels [123].

Paricalcitol has a lower risk of vascular calcification than calcitriol [124,125]. In experimental CKD vascular calcification, calcitriol (20 ng/kg) and paricalcitol (100 ng/kg) (dosages just sufficient to decrease PTH levels) reduced neointimal vascular calcium content and aortic gene expression of osteoblastic activity markers [126]. However, a higher paricalcitol (400 ng/kg) dose increased calcification and expression of osteoblast transcription factors.

**VDR agonists as immunomodulatory agents in autoimmune diseases and transplantation**

VDR is expressed in most cells of the immune system, including macrophages and dendritic cells, and CD4+ and CD8+ T-lymphocytes. 1-α-Hydroxylase in macrophages, dendritic cells and skin keratinocytes is stimulated by cytokines but not by PTH, and is not inhibited by calcitriol [127]. In inflammatory/ granulomatous disorders, macrophage 1-α-hydroxylase is not suppressed by the excessive calcitriol in the circulation. However, in kidney disease, peripheral blood monocyte 1-α-hydroxylase is exquisitely sensitive to feedback inhibition by physiological concentrations of serum 1,25(OH)D [128]. VDR activation inhibits Th1 cell, promotes Th2 cell development, and modulates the function of macrophages and dendritic cells, favouring self-tolerance and induction of regulatory CD4+CD25+ T-cells [129,130]. These properties are related to transrepression by 1,25(OH)D of inflammatory cytokines that may be related to interference with NF-κB activation [86].

Topical VDR agonists are effective in the clinical psoriasis [131]. Experimentally, VDR agonists prevent systemic lupus erythematosus (SLE) in MRLlpr/lpr mice, allergic encephalomyelitis, collagen-induced arthritis, Lyme’s disease, inflammatory bowel illness and autoimmune diabetes in non-obese diabetic mice [132–135]. VDR agonists are synergistic with immunosuppressive agents such as cyclosporine A, mycophenolate mofetil and sirolimus in murine models of graft tolerance [136]. In experimental murine SLE, calcitriol improved kidney disease and survival, similar to high doses of steroids, findings that require confirmation [137–139].

VDR polymorphisms have been studied for susceptibility and severity of lupus [140]. Most studies are small and comprise mainly Asian populations. Some found associations between genotype BB, SLE and lupus nephritis [141], while no association was found for the BsmI and FokI VDR polymorphisms [142,143]. In lupus patients, the prevalence of 25(OH)D deficiency is high and especially severe in cases of renal disease and photosensitivity [144,145]. 25(OH)D deficiency is associated with higher lupus disease activity, and its prevalence was higher in poor outcome groups, such as African American and Hispanic patients [146,147]. SLE leads to a higher rate of premature cardiovascular disease (up to 50 times vs controls), but the relationship to 25(OH)D deficiency is unknown [148–150]. Some authors include therapy of 25(OH)D deficiency in the management of risk factors for cardiovascular disease in chronic inflammatory disorders [151,152].

In human kidney transplantation, the prevalence of 25 (OH)D and 1,25(OH)D deficiency is very high in the first year post-transplant [153], and low 1,25(OH)D levels predict delayed graft function and poor outcomes, such as cancer and death [154]. High-dose VDR activator is required to control hyperparathyroidism without apparent severe adverse events [155]. However, clinical studies on VD status, immune function, and graft and patient survival are scarce. Clearly, we need randomized clinical trials to determine the target serum 25(OH)D levels that modulate the immune system, enhance the activity of current immunomodulators, and especially improve cardiovascular and overall prognosis of patients with chronic inflammatory diseases, including kidney transplantation.

**Vitamin D deficiency, VDR activation, glucose metabolism and metabolic syndrome**

Experimental studies and clinical observations suggest an association between VD deficiency, abnormal glucose metabolism, type 1 and type 2 diabetes mellitus (DM), and metabolic syndrome. Modulation of the immune system may preserve long-term beta-cell function and prevent type 1 DM [1]. Calcitriol inhibits pancreatic β cell inflammation and the onset of type 1 DM in non-obese diabetic-
Fig. 3. Non-classical biological actions of 1,25(OH)D–VDR interaction. Non-calciotropic consequences of VDR activation that may contribute to the impact of vitamin D deficiency on outcome in patients with and without CKD. ANP, atrial natriuretic peptide; AT II, angiotensin II; AT1R, angiotensin 1 receptor; Bcl2 (B-cell lymphoma 2 protein) and Bax (Bcl2-associated X protein) are proteins of Bcl2 family that protect from and promote apoptosis, respectively; CEBP/β, transcription factor that regulates growth and differentiation and suppresses cyclin D1 signature; EGFR, epidermal growth factor receptor; γ-IFN, gamma interferon; p21 and p27 are genes that control cellular proliferation; GDNF, glial cell line-derived neurotrophic factor; GMCSF, granulocyte–macrophage colony-stimulating factor; NF-κB, nuclear factor κ B; RAAS, renin–angiotensin–aldosterone system; RR, renin receptor; TGF-α, transforming growth factor-α; TGF-β, transforming growth factor-β; VEGF, vascular endothelial growth factor.
Fig. 4. General overview of CKD, vitamin D deficiency and renal–cardiovascular outcomes. Multiple factors contribute to 25(OH)D and 1,25(OH)D deficiency in CKD. Both 25(OH)D and 1,25(OH)D deficiency contribute to multiple pathophysiologic processes that may impact progression of CKD and its complications leading to increased morbidity and mortality. AMI, acute myocardial infarction; CKD, chronic kidney disease; DBP, VD-binding protein; ESRD, end-stage renal disease; FGF-23, fibroblastic growth factor 23; GFR, glomerular filtration rate; LV, left ventricular; PAD, peripheral arterial disease; RAAS, renin-angiotensin-aldosterone system.
prone mice, and reduces streptozotocin-induced diabetes [156–158]. In humans, vitamin D supplementation reduces the risk of developing type 1 DM [159–161]. In healthy individuals, there is an inverse correlation between serum 25(OH)D and glucose concentration or insulin resistance [162,163]. In type 2 DM, cholecalciferol decreased plasma 25(OH)D and glucose concentration or insulin resistance in some patients, whereas blood glucose was not altered in others [164]. In observational studies, low 25(OH)D levels are associated with reduced insulin sensitivity, increased risk of metabolic syndrome, and type 2 DM [165–167]. Clinical trials suggest that combined vitamin D and calcium supplementation may prevent type 2 DM in high-risk populations such as people with glucose intolerance and CKD [168]. Nevertheless, there were important limitations such as few subjects, short duration, and different formulations of vitamin D and calcium supplementation.

Several potential mechanisms may account for the action of vitamin D on glucose and insulin metabolism [162]. VDR stimulates insulin secretion, insulin receptor expression and insulin responsiveness [169–171], and oral cholecalciferol increased insulin secretion post-glucone load in type 2 DM patients [172]. Indirectly, VDR activation may reverse the decreased insulin sensitivity associated with increased PTH activity [173,174]. However, some studies did not show consistent results [172,175,176]. In dialysis patients, VDR activation may increase insulin secretion and sensitivity, and glucose uptake [172,177,178]. The specific role of vitamin D therapy (non-active or active analogues) in patients with and without vitamin D deficiency and metabolic syndrome or DM requires further study.

Additionally, calcitriol suppresses cell growth and regulates apoptosis, epidermal differentiation, anti-microbial responses, and muscle and nervous system function [179–184] (Figure 3). Different therapeutic applications are being explored, including cancer therapy.

Conclusions

Vitamin D deficiency, defined as serum 25(OH)D levels <20 ng/mL, is a common condition in the general population and in chronic inflammatory disorders, especially in CKD, which favours the development of metabolic bone disease. Current clinical and experimental evidence strongly suggest that vitamin D deficiency is a new risk factor for progression of kidney and cardiovascular disease. This relationship is most evident in CKD. In CKD patients, it is likely that therapy with nutritional vitamin D, calcitriol and/or VDR activators improves cardiovascular outcomes and patient survival. The widespread expression of VDR in many organ systems constitutes the biological basis for the pleiotropic and non-skeletal actions of vitamin D. These properties include RAAS inhibition, endothelial protection, immune modulation and anti-inflammatory actions. In this regard, vitamin D deficiency is associated with insulin resistance, left ventricular hypertrophy, proteinuria, atherogenicity, decreased thrombolysis, immune imbalances, susceptibility to infections and perpetuation of inflammation (Figure 4). Studies on vitamin D and survival have generated controversy because of the observational design or short follow-up in clinical trials. Further clinical trials should more accurately define the precise therapeutic agent, dose, timing, monitoring parameters and indications of vitamin D therapy. Meanwhile, simple and relatively inexpensive therapeutic measures, such as supplementing ergocalciferol or cholecalciferol to normalize serum 25(OH)D, seem warranted. Studies addressing the biological actions of VDR activators should be performed in patients with optimized 25(OH)D levels. Otherwise, it is difficult to conclude that, in vivo, they have intrinsic properties different from natural vitamin D.

Conflict of interest statement. None declared.

References

19. Visser M, Deeg DJ, Lips P. Low vitamin D and high parathyroid hormone levels as determinants of loss of muscle strength and muscle mass (sarcopenia): the Longitudinal Aging Study Amsterdam. J Clin Endocrinol Metab 2003; 88: 5766–5772


82. The VITAL Study. American Society of Nephrology Annual Meeting (ASN Renal Week), San Diego, CA, 2009
90. Dunlop TW, Vaisanen S, Frank C et al. The genes of the coactivator TIF2 and the corepressor SMRT are primary 1α, 25(OH)2D3 targets. J Steroid Biochem Mol Biol 2004; 89: 257–260
107. Pörsti IH. Expanding targets of vitamin D receptors activation: TIF2 and the corepressor SMRT are primary 1α, 25(OH)2D3 targets. J Steroid Biochem Mol Biol 2004; 89: 257–260


111. Boddy N, Ayus JC, Achingger S et al. Activated vitamin D attenuates left ventricular abnormalities induced by dietary sodium in Dahl salt-sensitive animals. Proc Natl Acad Sci USA 2007; 104: 16810–16815


